Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Screen time

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    296 result(s) found for: Screen time. Displaying page 8 of 15.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2019-003419-68 Sponsor Protocol Number: HepBTer Start Date*: 2020-12-18
    Sponsor Name:Academic Medical Center (AMC)
    Full Title: From fungus to virus, a phase 2a clinical trial investigating the safety and efficacy of terbinafine in chronic hepatitis B patients
    Medical condition: Chronic hepatitis B infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10052552 Hepatitis B virus LLT
    20.1 10021881 - Infections and infestations 10047450 Viral hepatitis B LLT
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    20.0 100000004848 10019743 Hepatitis B virus (HBV) LLT
    20.0 10021881 - Infections and infestations 10019737 Hepatitis B carrier LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004972-32 Sponsor Protocol Number: CQVM149C2201 Start Date*: 2022-06-23
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A Phase II, double-blind, randomized, multiple dose, cross over, three-treatment, three-period, six sequence placebo controlled trial to evaluate efficacy, pharmacokinetics (PK), pharmacodynamics (...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Trial now transitioned) PL (Trial now transitioned) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003590-24 Sponsor Protocol Number: LPL104884 Start Date*: 2006-03-01
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: LPL104884: A multicenter, randomized, double-blind, placebocontrolled, parallel-group, dose-ranging study of SB-480848, an oral lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, in subje...
    Medical condition: SB-480848 is under developement as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed) EE (Completed) HU (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-000358-13 Sponsor Protocol Number: A3921187 Start Date*: 2014-12-04
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3b/4 RANDOMIZED DOUBLE BLIND STUDY OF 5 MG OF TOFACITINIB WITH AND WITHOUT METHOTREXATE IN COMPARISON TO ADALIMUMAB WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATO...
    Medical condition: Moderately to severely active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) EE (Completed) LT (Completed) LV (Completed) GB (Completed) ES (Completed) PL (Completed) BG (Completed) RO (Completed) DE (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2010-018414-69 Sponsor Protocol Number: 4305-029 Start Date*: 2010-05-23
    Sponsor Name:Merck & Co., Inc.
    Full Title: "Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y la eficacia de MK-4305 en pacientes con insomnio primario -Es...
    Medical condition: Insomnio Primario /Primary Insomnia
    Disease: Version SOC Term Classification Code Term Level
    11 10036701 Insomnio primario LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GB (Completed) FI (Completed) SE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004006-54 Sponsor Protocol Number: PDY16744 Start Date*: 2021-03-09
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: Phase 2, multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of BIVV020 in adults with chronic inflammatory demyelinating polyneuropath...
    Medical condition: Chronic inflammatory demyelinating polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10077384 Chronic inflammatory demyelinating polyneuropathy LLT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000068-86 Sponsor Protocol Number: AROAAT2002 Start Date*: 2019-07-01
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
    Medical condition: alpha-1 antitrypsin deficiency (AATD)-associated liver disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004850 10001806 Alpha-1 anti-trypsin deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001085-17 Sponsor Protocol Number: P1V-S01-03-06 Start Date*: 2007-08-22
    Sponsor Name:University of Bristol
    Full Title: Further development of a new model of GAD: The effect of a clinically effective and non−effective dose of lorazepam on CO2 induced anxiety
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018075 Generalised anxiety disorder LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000320-40 Sponsor Protocol Number: SLx-2101-07-05 Start Date*: 2007-06-14
    Sponsor Name:Surface Logix, Inc.
    Full Title: A pilot Phase IIa randomised, double blind, placebo-controlled, crossover study to examine the safety, tolerability and pharmacodynamic effects on blood pressure of repeat oral doses of SLx-2101 5,...
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005228-18 Sponsor Protocol Number: FFA106783 Start Date*: 2007-01-12
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200mcg Twice Daily, GW685698X 200mcg and 400mcg Once Daily in the ...
    Medical condition: Persistent asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001659-24 Sponsor Protocol Number: OC000459/010/07 Start Date*: 2008-05-12
    Sponsor Name:Oxagen Ltd.
    Full Title: A dose-finding study of the effects of OC000459 on responses to allergen challenge in the Vienna chamber in subjects known to suffer from grass pollen induced allergic rhinitis: a randomised, doubl...
    Medical condition: Allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004602-17 Sponsor Protocol Number: 031-201-00186 Start Date*: 2018-03-12
    Sponsor Name:Otsuka Pharmaceutical
    Full Title: A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System with Healthcare Professionals and Adult Subjects with Schizo...
    Medical condition: Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001877-13 Sponsor Protocol Number: TMT107235 Start Date*: 2006-08-24
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, double-dummy, parallel-group, placebo-controlled study comparing correlates of brain functional activation before and after treatment with placebo, active comparator par...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003391-40 Sponsor Protocol Number: 2020-KEP-456 Start Date*: 2020-12-17
    Sponsor Name:London School of Hygiene and Tropical Medicine
    Full Title: Intramuscular tranexamic acid for the treatment of symptomatic mild traumatic brain injury in older adults: a randomised, double-blind, placebo-controlled trial.
    Medical condition: Mild traumatic brain injury.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10060690 Traumatic brain injury LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-005707-42 Sponsor Protocol Number: A090624 Start Date*: 2007-07-23
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: A single centre phase II study of Interleukin 1 receptor antagonist in the treatment of severe Traumatic Brain Injury
    Medical condition: Severe Traumatic Brain Injury
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060690 Traumatic brain injury LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002531-29 Sponsor Protocol Number: VIS649-201 Start Date*: 2020-03-24
    Sponsor Name:Visterra, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Nephropathy
    Medical condition: Immunoglobulin A (IgA) Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-008692-33 Sponsor Protocol Number: 2008-242 Start Date*: 2009-04-21
    Sponsor Name:Department of Urology, Herlev Hospital
    Full Title: Evaluation of cytotoxicity and genetic changes of high dose vitamin C infusions in castration resistant metastatic human prostate cancer.
    Medical condition: The effect of high dose intravenous weekly vitamin c infusion in castration resistant human prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004244-37 Sponsor Protocol Number: 13HH1824 Start Date*: 2014-02-21
    Sponsor Name:Imperial College London | Imperial College NHS Healthcare Trust
    Full Title: The control of brain networks after traumatic brain injury: a neuroimaging and neuropsychological study of dopamine and cognition
    Medical condition: Traumatic Brain Injury
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004863 10060690 Traumatic brain injury LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004249-17 Sponsor Protocol Number: NCTU:6831 Start Date*: 2014-02-12
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: A randomised, placebo controlled trial of extra-oesophageal reflux treatment in the management of upper respiratory symptoms. [TOPPITS: Trial of Proton Pump Inhibitors in Throat Symptoms]
    Medical condition: Persistent throat symptom - globus, hoarseness, throat clearing, throat discomfort, choking spasms, excess mucus/postnasal drip, otherwise unexplained night time cough of choking.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021531-13 Sponsor Protocol Number: UCL/10/0035 Start Date*: 2011-02-17
    Sponsor Name:Joint UCLH and UCL Biomedical Research Unit
    Full Title: Multi-centre, randomised, double-blind phase II study comparing cediranib (AZD2171) plus gefitinib (Iressa, ZD1839) with cediranib plus placebo in subjects with recurrent/progressive glioblastoma (...
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 23 03:22:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA